Gramics Bio Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series A
  • (Cancelled)

  • Investors
  • 5

Gramics Bio General Information

Description

Developer of non-viral gene therapy technology designed to enable durable and cell-type-specific deoxyribonucleic acid delivery for genetic medicine. The company engineers synthetic deoxyribonucleic acid sequences, integrates artificial intelligence with high-throughput screening, and supports programmable gene delivery using lipid nanoparticle systems, enabling biotechnology and pharmaceutical companies to develop durable and repeatable gene therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • First Floor
  • 85 Great Portland Street
  • London W1W 7LT
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Corporate Office
  • First Floor
  • 85 Great Portland Street
  • London W1W 7LT
  • England, United Kingdom

Gramics Bio Timeline

20252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gramics Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series A) Cancelled Generating Revenue
5. Seed Round Cancelled Generating Revenue
4. Accelerator/Incubator 19-Sep-2024 Completed Generating Revenue
3. Seed Round 19-Jun-2024 Completed Generating Revenue
2. Accelerator/Incubator 01-May-2024 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Gramics Bio’s complete valuation and funding history, request access »

Gramics Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Gramics Bio’s complete cap table history, request access »

Gramics Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gramics Bio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Science Entrepreneur Club Accelerator/Incubator
Cystic Fibrosis Foundation Limited Partner Minority
Deep Science Ventures Venture Capital Minority
Stevenage Bioscience Catalyst Accelerator/Incubator
The Francis Crick Institute Accelerator/Incubator
To view Gramics Bio’s complete investors history, request access »

Gramics Bio FAQs

  • When was Gramics Bio founded?

    Gramics Bio was founded in 2024.

  • Where is Gramics Bio headquartered?

    Gramics Bio is headquartered in London, United Kingdom.

  • What is the size of Gramics Bio?

    Gramics Bio has 3 total employees.

  • What industry is Gramics Bio in?

    Gramics Bio’s primary industry is Biotechnology.

  • Is Gramics Bio a private or public company?

    Gramics Bio is a Private company.

  • What is Gramics Bio’s current revenue?

    The current revenue for Gramics Bio is .

  • How much funding has Gramics Bio raised over time?

    Gramics Bio has raised $318K.

  • Who are Gramics Bio’s investors?

    Science Entrepreneur Club, Cystic Fibrosis Foundation, Deep Science Ventures, Stevenage Bioscience Catalyst, and The Francis Crick Institute have invested in Gramics Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process